AstraZeneca’s Lynparza approved by NHS England

Approvals

NHS England has approved the use of AstraZeneca’s Lynparza (olaparib) for the treatment of patients with breast cancer and prostate cancer. This approval means men with advanced prostate cancer and women with HER2-negative early breast cancer who are at high risk of the disease returning will be offered olaparib through the NHS in England. The decision has already received praise from charities and clinicians.

The drug, taken as a tablet, is a type of targeted drug called a PARP inhibitor, which prevents cancer cells from repairing. It targets cancers with BRCA1 or BRCA2 mutations, stopping the cancerous cells from repairing their DNA therefore causing them to die.

Clinical trials have shown that prostate cancer patients treated with olaparib live for an additional “average of six months” according to NHS England. It has also been shown to reduce the risk of the BRCA-mutant, HER2-negative early breast cancer from returning within four years by almost a third.

It is expected that around 550 men with prostate cancer and 300 women with HER2-negative early breast cancer will be eligible for the drug each year in England.

NHS England chief executive, Amanda Pritchard commented: “Olaparib could have a huge impact on patients with a range of cancer types, giving many a better chance of survival while offering those with advanced forms of the disease precious extra months to live.”

Johann De Bono, professor in Experimental Cancer Medicine at the Institute of Cancer Research (ICR), added: “Olaparib is an important example of how understanding the underlying genetics of patients, and their tumours’ genomics, can be used to design highly targeted precision medicines. For patients with advanced prostate cancer and mutations in BRCA1 or BRCA2, these recommendations will be life-changing.”

UKHSA opens new vaccine research centre in Wiltshire to prepare for future pandemics

Ministers have opened a new vaccine research centre at the UKHSA Porton Down campus in Wiltshire, intended to prepare for 'disease x', the next possible pandemic pathogen.

Bristol Myers Squibb’s Sotyktu recommended to treat adult patients with psoriasis on the NHS

Bristol Myers Squibb has announced that NICE has recommended Sotyktu (deucravacitinib) for use on the NHS in England as a new treatment option for adult patients with moderate-to-severe plaque psoriasis.

Report finds NHS may miss out on new drugs due to rising costs

Figures from a team at the University of York, the London School of Economics and Political Science (LSE), and the London School of Hygiene and Tropical Medicine (LSHTM) have revealed that the total cost of prescription medicines to NHS England reached a new high of £17.2bn in 2021-22, and that since 2018, NHS spending on branded medicines have been increasing by over 5% annually.

Trade union Unite calls for GSK staff walkouts over pay increase disputes

UK-based trade union Unite were pushing for staff walkouts at several GSK manufacturing sites due to disputes regarding pay increases, however to date there have been no updates as to whether GSK have extended another offer.

Pharmacists in England given wider prescribing powers to relieve GP pressure

NHS England has announced that pharmacists in England will be given wider prescribing powers to relieve pressure put on GPs.

UKHSA opens new vaccine research centre in Wiltshire to prepare for future pandemics

Bristol Myers Squibb’s Sotyktu recommended to treat adult patients with psoriasis on the NHS

Report finds NHS may miss out on new drugs due to rising costs

Trade union Unite calls for GSK staff walkouts over pay increase disputes

Pharmacists in England given wider prescribing powers to relieve GP pressure

Pharmafocus

Categories

Social Footprints